Intussusception Market 2024-2033: Competitor Assessment, New Trends, Share Analysis And Global Key Players

The intussusception market size has grown strongly in recent years. It will grow from $4.22 billion in 2023 to $4.45 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to improved diagnostic capabilities, increased awareness and education, global healthcare infrastructure growth, research and development investments, collaboration among healthcare entities..

The intussusception market size is expected to see steady growth in the next few years. It will grow to $5.3 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to continued medical education initiatives, pediatric vaccination programs, global efforts in pediatric healthcare, focus on postoperative care, rising demand for pediatric gastrointestinal research, telemedicine and remote healthcare access.. Major trends in the forecast period include advancements in diagnostic imaging, minimally invasive treatment approaches, development of pediatric-specific interventions, research on etiology and risk factors, global epidemiological studies, implementation of vaccination programs, telemedicine for diagnosis and consultation..

Market Overview -
Intussusception is a medical condition in which one portion of the intestine slides into an adjacent section of the intestine, blocking the flow of food, fluids, and gas through the affected part of the intestine, leading to symptoms such as severe abdominal pain, vomiting, and bloody stools. It is usually diagnosed based on the symptoms, physical examination, and imaging tests.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13466&type=smp

Increasing Incidence of Intestinal Disorder to Drive Intussusception Market Growth
The rising incidence of intestinal disorders is expected to propel the growth of the intussusception market going forward. An intestinal disorder refers to any medical condition or health issue that affects the normal functioning of the intestines, which are parts of the digestive system responsible for absorbing nutrients and eliminating waste from the body. An increasing incidence of intestinal disorders such as inflammatory bowel disease and gastrointestinal cancers can lead to earlier diagnosis, improved treatment options, and enhanced support for intussusception patients, ultimately benefiting their health and well-being. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based health organization dedicated to eliminating cancer, gastrointestinal cancers increased by 3.18% to 348,840 compared to 338,090 in 2021 in the United States. Therefore, the rising incidence of intestinal disorders will drive the growth of the intussusception market.

Competitive Landscape -
Major companies operating in the intussusception market report are Pfizer Inc., Merck & Co. Inc, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline plc, Stryker Corporation, Boston Scientific Corporation, Biogen Inc., Olympus Corporation, GE HealthCare Technologies Inc. , Steris Plc, Cook Medical LLC, Shimadzu Corporation, Carestream Health, CONMED Corporation, Janssen Pharmaceuticals Inc., EndoChoice Holdings Inc. , Fujifilm Healthcare Solutions, Basilea Pharmaceutica Ltd., Richard Wolf GmbH, Karl Storz SE And Co. KG, Eizoflex Co. Ltd., Arena Pharmaceuticals Inc.

Companies Pioneering NHE3 Inhibitor Therapy To Elevate Intussusception Treatment Standard
Major companies operating in the intestinal pseudo-obstruction treatment market are developing novel drug therapies, such as NHE3 inhibitor treatment therapy, to provide reliable services to customers. NHE3 inhibitor treatment therapy is a medication that works by inhibiting the Sodium-Proton-Exchanger subtype 3 (NHE3) in the gut. For instance, in April 2022, Ardelyx Inc., a US-based biopharmaceutical company, introduced IBSRELA, an NHE3 inhibitor treatment for irritable bowel syndrome with constipation (IBS-C) in adults, potentially improving gastrointestinal motility. IBSRELA treatment therapy works by inhibiting or blocking the activity of the Sodium-Hydrogen Exchanger 3 (NHE3) protein. IBSRELA's approval was based on two Phase 3 trials with over 1,200 IBS-C patients, where it significantly improved abdominal pain and bowel movements, meeting the primary endpoint, with improvements observed as early as Week 1 and sustained for 26 weeks in the long-term trial.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/intussusception-global-market-report

Key Segments -

The intussusception market covered in this report is segmented -
1) By Type: Idiopathic Intussusception, Secondary Intussusception
2) By Treatment: Enema Reduction, Surgery, Other Treatment
3) By Diagnosis: Barium Enema, Ultrasound, X-Ray, Computerized Tomography (CT)
4) By End-User: Hospitals, Clinics, Other End-User

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.